Research compendium

Pemvidutide

Pemvidutide is a peptide agonist of GLP-1 and glucagon receptors. Its liver research illustrates why fat, inflammatory activity and fibrosis cannot be summarized as one liver-health outcome.

This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.

What is established and what remains a hypothesis

Keep source limits and editorial status visible. A proposed mechanism should not be presented as a confirmed property in every context.

Is the source the original work, a review or a later interpretation?
Has the observation been reproduced under independent conditions?
Does the material defined in the paper match the entity named in this entry?

Find readings for this question

Mechanism described in the literature

The dual profile identifies two pharmacological targets. Selected trials evaluate the complete molecule without experimentally separating receptor contributions or establishing fat change as the sole explanation for all histological findings.

Classification

Dual GLP-1 and glucagon receptor agonist peptide

Other names

Pemvidutide
ALT-801

MRI addresses a specific question

In the Journal of Hepatology trial in adults with MASLD, MRI-measured liver-fat fraction declined relative to placebo. This was the primary endpoint over twelve weeks. It quantifies fat but does not replace histological fibrosis assessment.

IMPACT did not show uniform findings

In IMPACT adults with MASH and F2–F3 fibrosis, MASH resolution without worsening fibrosis differed significantly from placebo at twenty-four weeks. In the same population, fibrosis improvement without worsening MASH did not reach statistical significance. Both findings must be presented together.

Keeping conclusions within the data

Resolution of one histological component does not establish change in another. Conversely, lack of a statistically significant difference does not prove that every effect is impossible; it defines what that trial established. Comparisons must retain measurement method, population, duration and response definition.

Questions and answers

Does less liver fat demonstrate less fibrosis?

No. They are different characteristics requiring specific measurements; neither automatically substitutes for the other.

Did IMPACT confirm every histological endpoint?

No. MASH-resolution differences and nonsignificant fibrosis-improvement findings are distinct outcomes of the same trial.